Status:
COMPLETED
Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesterolaemia
Eligibility:
All Genders
18-80 years
Brief Summary
This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek...
Eligibility Criteria
Inclusion
- Patients with hypercholesterolaemia who are already in treatment with rosuvastatin according to the approved SPC for no longer than 1 month prior to study entry
- Patients that are able to read, understand and sign the Patient Information \& Consent Form
- Patients that are willing to comply with all study requirements
Exclusion
- Patients that are likely not to comply with all study requirements
- Patients that currently participate or have participated in a 3 months period prior to study entry in another clinical trial
- Female of child bearing potential that do not use a reliable method of contraception. Pregnancy or lactation.
- Patients that meet any of the contraindications described in the approved SPC
Key Trial Info
Start Date :
December 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
810 Patients enrolled
Trial Details
Trial ID
NCT00695539
Start Date
December 1 2007
End Date
December 1 2008
Last Update
October 5 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alexandroupoli, Greece
2
Research Site
Athens, Greece
3
Research Site
Iraklio, Crete, Greece
4
Research Site
Larissa, Greece